News|Articles|December 21, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-01-04-2017
  • Volume 12
  • Issue 1

Vetter Begins Manufacturing on Clinical Syringe Filling Line

The company has manufactured double-digit number of batches on the new filling line, for use in early-stage clinical trials.

On Dec. 13, 2016, Vetter announced that its new clinical syringe line has manufactured double-digit number of batches for use in early-stage clinical trials. The line is part a growth expansion at the company’s Skokie facility. This expansion includes an increase in storage capability designed to manage the continued growth in syringe fills and larger batch sizes. This storage expansion includes six new chest freezers, two upright freezers, and two refrigerator units. The company expects storage will be expanded by the end of the year to increase capacity by 150%. Vetter has also launched an aseptic syringe filling line.

Vetter’s Skokie facility is the company’s US clinical manufacturing site, providing development support for preclinical through Phase II injectables, primarily complex biologics. The facility, currently operating with a staff of more than 60, offers chemical analysis and microbiology labs, material preparation, and compounding functions. The facility includes cleanrooms, visual inspection capabilities, and GMP storage.

Source: Vetter


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.